Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 2, facilitated glucose transporter member 4 (GLUT4) is the primary insulin-regulated glucose transporter in mammals, predominantly expressed in skeletal muscle, adipose tissue, and cardiac muscle (UniProt, 2024; StatPearls, 2023). Unlike other members of the GLUT family, GLUT4 is uniquely stored in intracellular vesicles and only translocates to the plasma membrane in response to specific stimuli such as insulin or physical exercise (Wikipedia, 2024; PMC, 2019). This regulated movement is essential for maintaining systemic glucose homeostasis by allowing cells to rapidly increase glucose uptake from the bloodstream following a meal or during energy expenditure (MDPI, 2022). Dysfunction in GLUT4 expression or its trafficking mechanism is a hallmark of insulin resistance and is central to the pathogenesis of type 2 diabetes mellitus and metabolic syndrome (NCBI Gene, 2024; MDPI, 2024). Therapeutic strategies often focus on enhancing GLUT4 translocation or expression, as seen with drugs like thiazolidinediones and metformin, to improve insulin sensitivity (StatPearls, 2023; Patsnap, 2024). Conversely, certain medications, such as HIV protease inhibitors, can inadvertently inhibit GLUT4, leading to adverse metabolic effects like hyperglycemia and lipodystrophy (MDPI, 2022; ResearchGate, 2025).
GLUT4 facilitates the ATP-independent diffusion of glucose across the plasma membrane down its concentration gradient (StatPearls, 2023). In the basal state, approximately 90% of GLUT4 is sequestered within specialized intracellular compartments called GLUT4 storage vesicles (GSVs) (Wikipedia, 2024; MDPI, 2024). Upon insulin stimulation or muscle contraction, signaling cascades involving PI3K/Akt or AMPK pathways trigger the translocation of these vesicles to the cell surface, where they fuse with the plasma membrane to increase glucose uptake (Cell Metabolism, 2007; PMC, 2019).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 4 (GLUT4).